Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- RDHL
- Price
- 2.27
- Stock movement down
- -0.14 (-5.84%)
- Company name
- Redhill Biopharma Ltd
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Drug Manufacturers - Specialty & Generic
- Market cap
- 2.91M
- Ent value
- -
- Price/Sales
- 0.11
- Price/Book
- -
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -10.43%
- Trailing P/E
- 0.51
- Forward P/E
- -
- PEG
- -
- EPS growth
- -
- 1 year return
- -99.20%
- 3 year return
- -88.66%
- 5 year return
- -77.40%
- 10 year return
- -56.39%
Last updated: 2025-04-15
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
RDHL does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | 0.51 |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | 0.03 |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 0.11 |
| Price to Book | - |
| EV to Sales | - |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 1.28M |
| EPS (TTM) | - |
| FCF per share (TTM) | - |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 27.39M |
| Gross profit (TTM) | 9.39M |
| Operating income (TTM) | -24.30M |
| Net income (TTM) | 5.74M |
| EPS (TTM) | - |
| EPS (1y forward) | - |
Margins
Loading...
Margins data
| Gross margin (TTM) | 34.28% |
| Operating margin (TTM) | -88.73% |
| Profit margin (TTM) | 20.96% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 7.00M |
| Net receivables | 5.95M |
| Total current assets | 27.05M |
| Goodwill | -60.02M |
| Intangible assets | 5.59M |
| Property, plant and equipment | 2.25M |
| Total assets | 35.04M |
| Accounts payable | 3.11M |
| Short/Current long term debt | 2.28M |
| Total current liabilities | 28.19M |
| Total liabilities | 31.57M |
| Shareholder's equity | 3.47M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -15.43M |
| Capital expenditures (TTM) | 8.34K |
| Free cash flow (TTM) | -15.44M |
| Dividends paid (TTM) | 1.61M |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | - |
| Return on Assets | - |
| Return on Invested Capital | - |
| Cash Return on Invested Capital | - |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 2.49 |
| Daily high | 2.49 |
| Daily low | 2.20 |
| Daily Volume | 18K |
| All-time high | 12368.75 |
| 1y analyst estimate | 19000.00 |
| Beta | 3.67 |
| EPS (TTM) | - |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | - |
Downside potential
Loading...
Downside potential data
| RDHL | S&P500 | |
| Current price drop from All-time high | -99.98% | -12.04% |
| Highest price drop | -99.98% | -56.47% |
| Date of highest drop | 4 Apr 2025 | 9 Mar 2009 |
| Avg drop from high | -60.95% | -11.07% |
| Avg time to new high | 131 days | 12 days |
| Max time to new high | 2473 days | 1805 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
2.91M
Marketcap category
Small-cap
Description
RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its pipeline consists of five therapeutic candidates, which are in clinical development include opaganib for treating patients hospitalized with SARS-CoV-2 severe COVID-19 pneumonia, advanced unresectable cholangiocarcinoma, prostate cancer, and nuclear radiation protection; RHB-107 (upamostat) for treating outpatients infected with SARS-CoV-2 (COVID-19 disease) and advanced unresectable cholangiocarcinoma; RHB-104 for Crohn's disease; RHB-102 (Bekinda) for the treatment of acute gastroenteritis and gastritis, irritable bowel syndrome with diarrhea, and oncology support anti-emetic; and RHB-204 for pulmonary nontuberculous mycobacteria infections caused by mycobacterium avium complex. The company was incorporated in 2009 and is headquartered in Tel Aviv, Israel.
Employees
53
Website
Investor relations
-
SEC filings
CEO
Dror Ben-Asher
Country
USA
City
Tel Aviv
Stock type
American depositary share
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page